JP7825633B2 - ガレクチン－３に対する抗体及びその使用方法 - Google Patents

ガレクチン－３に対する抗体及びその使用方法

Info

Publication number
JP7825633B2
JP7825633B2 JP2023558307A JP2023558307A JP7825633B2 JP 7825633 B2 JP7825633 B2 JP 7825633B2 JP 2023558307 A JP2023558307 A JP 2023558307A JP 2023558307 A JP2023558307 A JP 2023558307A JP 7825633 B2 JP7825633 B2 JP 7825633B2
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
lgals3
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023558307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501581A (ja
JP2024501581A5 (https=
Inventor
デイヴィッド スプリッグス
ダルマラオ タピ
イヴォ シー ロレンツ
トーマス イー ホワイト
Original Assignee
メモリアル スローン ケタリング キャンサー センター
ティーアールアイ－インスティテューショナル セラピューティクス ディスカバリー インスティテュート インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, ティーアールアイ－インスティテューショナル セラピューティクス ディスカバリー インスティテュート インコーポレイテッド filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2024501581A publication Critical patent/JP2024501581A/ja
Publication of JP2024501581A5 publication Critical patent/JP2024501581A5/ja
Application granted granted Critical
Publication of JP7825633B2 publication Critical patent/JP7825633B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023558307A 2020-12-08 2021-12-07 ガレクチン－３に対する抗体及びその使用方法 Active JP7825633B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122714P 2020-12-08 2020-12-08
US63/122,714 2020-12-08
PCT/US2021/062099 WO2022125482A1 (en) 2020-12-08 2021-12-07 Antibodies to galectin-3 and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024501581A JP2024501581A (ja) 2024-01-12
JP2024501581A5 JP2024501581A5 (https=) 2024-12-16
JP7825633B2 true JP7825633B2 (ja) 2026-03-06

Family

ID=81973696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558307A Active JP7825633B2 (ja) 2020-12-08 2021-12-07 ガレクチン－３に対する抗体及びその使用方法

Country Status (4)

Country Link
US (1) US20240026009A1 (https=)
EP (1) EP4259201A4 (https=)
JP (1) JP7825633B2 (https=)
WO (1) WO2022125482A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
CN118978593B (zh) * 2023-11-07 2025-07-15 深圳市睿盟创新生物科技有限公司 人半乳糖凝集素-3蛋白水平的测定方法及应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
JP2016519285A (ja) 2013-03-13 2016-06-30 クリエイティクス エルエルシー 膵臓がんを検出するための方法および組成物
WO2017119434A1 (ja) 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
WO2019068863A1 (en) 2017-10-05 2019-04-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies SPECIFIC BINDING MOLECULE DIRECTED AGAINST GALECTIN-3 PROTEIN
WO2019152895A1 (en) 2018-02-01 2019-08-08 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
AU2020201807A1 (en) 2015-05-30 2020-04-02 Molecular Templates, Inc. De-immunized, Shiga toxin A Subunit scaffolds and cell-targeting molecules comprising the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160156A2 (en) * 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016519285A (ja) 2013-03-13 2016-06-30 クリエイティクス エルエルシー 膵臓がんを検出するための方法および組成物
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
AU2020201807A1 (en) 2015-05-30 2020-04-02 Molecular Templates, Inc. De-immunized, Shiga toxin A Subunit scaffolds and cell-targeting molecules comprising the same
WO2017119434A1 (ja) 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
WO2019068863A1 (en) 2017-10-05 2019-04-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies SPECIFIC BINDING MOLECULE DIRECTED AGAINST GALECTIN-3 PROTEIN
WO2019152895A1 (en) 2018-02-01 2019-08-08 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof

Also Published As

Publication number Publication date
EP4259201A1 (en) 2023-10-18
JP2024501581A (ja) 2024-01-12
US20240026009A1 (en) 2024-01-25
EP4259201A4 (en) 2025-03-19
WO2022125482A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
US12466894B2 (en) Anti-MUC16 antibodies and uses thereof
US20260071005A1 (en) Bispecific her2 and cd3 binding molecules
JP7825633B2 (ja) ガレクチン－３に対する抗体及びその使用方法
US20250353915A1 (en) Antibodies to galectin-3 and methods of use thereof
AU2009245354C1 (en) Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
CA2928895C (en) Antibodies against ccr9 and applications thereof
CN119161481A (zh) 用于治疗的药剂、用途和方法
KR20210080400A (ko) 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체
TW202509070A (zh) Bdca2-標靶抗體及其用途
HK1238654A1 (en) Bispecific her2 and cd3 binding molecules
HK1238654B (en) Bispecific her2 and cd3 binding molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260224

R150 Certificate of patent or registration of utility model

Ref document number: 7825633

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150